AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.08), $0.13 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $46.1 million versus the consensus estimate of $45.36 million.

2018 Financial Guidance

Management projects 2018 revenue of approximately $190 million to $196 million. Adjusted EBITDA, a non-GAAP measure, is projected to be positive for 2018.

For earnings history and earnings-related data on AtriCure (ATRC) click here.